MMCM
RMD icon

Murphy & Mullick Capital Management’s ResMed RMD Stock Holding History

Murphy & Mullick Capital Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5K Hold
87
– – 0.01% 397
2025
Q4 		$21K Hold
87
– – 0.02% 396
2025
Q3 		$23.8K Hold
87
– – 0.02% 370
2025
Q2 		$23.7K Hold
87
– – 0.02% 359
2025
Q1 		$19.5K Hold
87
– – 0.02% 369
2024
Q4 		$19.9K Buy
+87
New +$20.9K 0.02% 363

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Murphy & Mullick Capital Management's RMD Position: Q1 2026 in Review

Murphy & Mullick Capital Management held its ResMed (RMD) position steady in Q1 2026 at 87 shares worth $19.5K. The position accounts for 0.01% of the portfolio, ranked #397.

Murphy & Mullick Capital Management first reported a position in RMD in Q4 2024 and has held it in 6 quarters since. The position peaked at $23.8K in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Murphy & Mullick Capital Management held 87 shares of ResMed worth $19.5K as of Q1 2026.
  • Murphy & Mullick Capital Management left its ResMed share count unchanged in Q1 2026.
  • ResMed made up 0.01% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #397 holding.
  • Murphy & Mullick Capital Management first reported a position in ResMed in Q4 2024 and has held it in 6 quarters since.
  • Murphy & Mullick Capital Management's ResMed position peaked at $23.8K in Q3 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.